# Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

> **NCT06816927** · PHASE2 · RECRUITING · sponsor: **Duke University** · enrollment: 92 (estimated)

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab
- **DRUG:** TMZ
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06816927
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2029-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816927, "Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06816927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*